ArticleAnalytical science advances2026
Identification of a Circular RNA as a Potential Diagnostic and Prognostic Biomarker in Breast Cancer Through Integrated Bioinformatic and Experimental Analyses.
Article in Analytical science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer (BC), which has complex molecular subgroups that contribute to a range of clinical outcomes, is still one of the top causes of morbidity and death among women globally. This challenge necessitates ongoing research to improve early detection, treatment strategies, and patient outcomes. Recent research has shown that circular RNAs (circRNAs) influence gene expression through various mechanisms, particularly by functioning as competing endogenous RNAs (ceRNAs). Moreover, numerous circRNAs have been implicated in the initiation and progression of various tumor types. Yet, the expression and functional roles of multiple circRNAs remain largely unexplored in specific cancers. In this study, circRNA expression data from three Gene Expression Omnibus datasets were analyzed to identify candidate circRNAs associated with BC. Reverse-transcription quantitative polymerase chain reaction (RT-qPCR) was performed to validate the candidate circRNAs in tissue samples from 24 BC patients. Using bioinformatic analyses, downstream target microRNAs and messenger RNAs of these circRNAs were probed for the construction of a ceRNA regulatory network. A combined number of 40 distinct circRNAs with differential expression were identified, among which hsa_circ_0000231 and hsa_circ_0011385 were selected based on their novelty and potential to function as ceRNAs, and a corresponding ceRNA network was built. RT-qPCR revealed that hsa_circ_0000231 is significantly upregulated in BC tissues compared to adjacent non-cancerous tissues. Additionally, based on bioinformatic investigations, hsa_circ_0000231/hsa-miR-5683/cyclin B1 regulatory axis was predicted. By combining cross-dataset computational screening with targeted experimental validation and diagnostic accuracy assessment, this study presents a systematic framework for translating high-throughput RNA data into quantifiable biomarker candidates with potential clinical relevance. These findings may contribute to the identification of a novel diagnostic and prognostic biomarker in BC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.